Our Technology

LBNano BioTechnologies (LBNano) develops state-of-the-art instrumentation for research and sensing applications. Our technologies are centered on two platforms: nanopore sensing and fluorescent assay. To develop next-generation liquid biopsy technologies for prevention, early detection, and prognosis of human diseases, we have designed easy-to-use, point-of-care (POC) devices for highly sensitive and selective detection and quantification of disease biomarkers.

One of our primary focuses is targeted at the improvement in the disease diagnosis accuracy. We do this by taking advantage of a panel of biomarkers, including microRNAs, proteins, proteases, metal ions, and even other metabolites. Furthermore, machine learning and artificial intelligence (AI) are used to guide biomarker panel design and for more effective data analysis. Our scientists and engineers have many years’ experience in designing low noise / background electric and fluorescent sensing systems, and have applied these unique skills to the particular needs of LBNano. To develop highly sensitive kits for detection of ultra-low concentrations of biomarkers in clinical samples, we work closely with our collaborators at Illinois Institute of Technology and the University of Missouri who invented various nanopore-based and fluorescence-based strategies for detection of nucleic acids, proteins, proteases, and metal ions. Building on their pioneered investigations, LBNano developed POC platforms for disease prevention and early diagnosis with high sensitivity and accuracy. Our devices can be used in either a clinician’s office, hospital or at home.